Ashwagandha is the most-studied adaptogen in clinical research, with over a dozen published double-blind, placebo-controlled human RCTs — a distinction that separates it from most herbs in the supplement market where clinical trial evidence is scarce. The consistency of findings across independent research groups is notable: ashwagandha reliably reduces self-reported and biochemical markers of stress, reduces serum cortisol, improves sleep quality, and in studies combining it with resistance training, significantly enhances muscle and strength gains compared to placebo.
The Chandrasekhar 2012 trial (Indian Journal of Psychological Medicine) remains the landmark cortisol study: N=64 adults with chronic stress, 8 weeks of KSM-66 ashwagandha extract 300mg twice daily, demonstrated a 27.9% reduction in serum cortisol vs a 2.3% increase in the placebo group. This is a large effect size for a non-pharmaceutical intervention and has been replicated directionally in multiple subsequent trials. The mechanism — HPA axis modulation through reduced CRH signaling rather than cortisol synthesis blocking — explains why ashwagandha produces physiological cortisol reduction without the pathological consequences of pharmacological cortisol suppression.
| Form | Standardization | RCT Evidence | Notes |
|---|---|---|---|
| KSM-66 (root only) | ≥5% withanolides by HPLC | 22+ RCTs — most extensively studied | Full-spectrum root extract; milk-processed extraction; preferred for most goals |
| Sensoril (root + leaf) | ≥10% withanolide glycosides + ≥32% oligosaccharides | 8+ RCTs | Higher withanolide content; some prefer for stress/anxiety specifically; may have slightly different withanolide profile |
| Generic root extract | Variable (2.5–5% typical) | Minimal — different from studied forms | Cheaper; bioequivalence to KSM-66/Sensoril not established; use if budget constrained, prefer branded if outcome-focused |
| Raw root powder | Unstandardized | Traditional use; not the form in RCTs | Traditional Ayurvedic use; significant batch-to-batch variation; not recommended for clinical outcomes |
Dose (from RCTs): KSM-66: 300mg 2×/day (600mg/day total) is the most studied dose across cortisol, stress, sleep, and testosterone trials; Sensoril: 125–250mg 2×/day typically studied; 8-week minimum trial before assessing effect (most RCTs show significant effect at 8 weeks; some benefit at 4 weeks for sleep).
Timing: Split dosing (morning + evening) used in most RCTs and reflects the split-dose pharmacokinetic rationale (withanolide half-life ~8–12 hours); evening dose may particularly support sleep; taking with food reduces rare GI discomfort; no significant interaction with caffeine documented.
Contraindications (clinically important): Pregnancy — animal studies show uterotonic effects; avoid entirely during pregnancy; hyperthyroidism (Graves' disease, toxic multinodular goiter, thyrotoxicosis) — ashwagandha stimulates thyroid hormone production; this can precipitate thyroid storm in susceptible individuals; Hashimoto's thyroiditis — complex; some benefit in reducing TSH, but immune modulation effects require physician supervision; autoimmune diseases broadly — ashwagandha has immunostimulatory effects that may worsen conditions like lupus, rheumatoid arthritis, multiple sclerosis; pre-surgical use — may enhance sedative effects of anesthesia; discontinue 2 weeks before scheduled surgery.
Side effects: Generally well-tolerated; most common: GI upset (nausea, loose stool) at higher doses — take with food; drowsiness at high doses (useful if taking at night, problematic if daytime); rare: thyrotoxicosis in individuals with pre-existing thyroid conditions (case reports); rare liver injury cases reported (likely high-dose leaf extract, not root extract at standard doses — causality unconfirmed).
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.